Related Experiment Video
Updated: Aug 26, 2026
Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
[Application of collagen-binding assay for von Willebrand disease]
Jing Zhou1, Yong-qian Jia, Hong Jiang
1Department of Clinical Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Insights
The collagen-binding assay (CBA) for von Willebrand factor (vWF) is a highly sensitive and specific diagnostic tool for von Willebrand disease (vWD). This reliable assay can replace other functional activity measurements for vWD diagnosis.
Area of Science:
- Hematology
- Clinical Diagnostics
- Biochemistry
Context:
- Von Willebrand disease (vWD) is a common inherited bleeding disorder.
- Accurate diagnosis of vWD relies on sensitive and specific laboratory assays.
- Current diagnostic methods for vWD have varying degrees of sensitivity and specificity.
Purpose:
- To evaluate the diagnostic performance of the collagen-binding assay (CBA) for von Willebrand factor (vWF) in patients with vWD.
- To compare the sensitivity and reproducibility of vWF: CBA with other established vWD diagnostic assays.
Summary:
- The study investigated the enzyme-linked immunosorbent assay (ELISA) based vWF: CBA for diagnosing vWD.
- Results showed significantly lower vWF: CBA levels in vWD patients compared to healthy individuals and those with other bleeding disorders (P < 0.001).
- vWF: CBA demonstrated high concordance (95.2%) with vWD diagnosis, outperforming other tested assays.
Impact:
- vWF: CBA is a highly sensitive, specific, and reproducible assay for diagnosing vWD.
- This assay offers a reliable alternative to vWF:RCoF and RIPA for assessing functional vWF activity.
- The ease of operation and high accuracy of vWF: CBA facilitate improved clinical diagnosis and management of vWD.
Objective:
To explore the application of collagen-binding assay for von Willebrand disease (vWD).
Methods:
We investigated the sensitivity and reproducibility of collagen-binding assays (CBA) of vWF using the enzyme-linked immunosorbent assay (ELISA) technique and compared CBA with 3 other assays for their ability to detect vWD.
Results:
It was found that the vWF: CBA level of plasma from patients with different types of vWD is lower than that from healthy donors, hemophilia and other bleeding disorders (P < 0.001). In general, the four assays have the capability to identify vWD from normal and other bleeding disorders, and can be used for diagnosing vWD. The concordance rates of the four assays on vWD are vWF: Ag 85.7%, vWF: Rcof 76.2%, RIPA 80.9%, vWF: CBA 95.2% respectively.
Conclusion:
vWF: CBA measured by ELISA is highly sensitive, specific and reproducible, and easy to operate. The measurement of the functional activity of vWF by vWF: Rcof or RIPA can be replaced by the more reliable vWF: CBA.
